• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identifying possible biomarkers of lower urinary tract symptoms using metabolomics and partial least square regression.利用代谢组学和偏最小二乘回归鉴定下尿路症状的潜在生物标志物。
Metabolomics. 2023 Sep 12;19(9):82. doi: 10.1007/s11306-023-02046-2.
2
Can We Rely Solely on the International Prostate Symptoms Score to Investigate Storage Symptoms in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement? Findings from a Cross-sectional Study.仅依靠国际前列腺症状评分能否调查与良性前列腺增生相关的下尿路症状男性的储尿症状?一项横断面研究的结果。
Eur Urol Focus. 2022 Mar;8(2):555-562. doi: 10.1016/j.euf.2021.03.004. Epub 2021 Mar 20.
3
Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.国际前列腺症状评分和核心下尿路症状评分评估男性下尿路症状。
BJU Int. 2012 May;109(10):1512-6. doi: 10.1111/j.1464-410X.2011.10445.x. Epub 2011 Aug 26.
4
The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).视觉前列腺症状评分是一种用于在全科医疗中识别和随访伴有良性前列腺增生的下尿路症状患者的简单工具(一项针对1359名患者的研究)。
Presse Med. 2018 Jul-Aug;47(7-8 Pt 1):e91-e98. doi: 10.1016/j.lpm.2018.06.011. Epub 2018 Jul 31.
5
Hypovitaminosis D is associated with lower urinary tract symptoms and benign prostate hyperplasia in type 2 diabetes.维生素D缺乏与2型糖尿病患者的下尿路症状及良性前列腺增生有关。
Andrology. 2015 Nov;3(6):1062-7. doi: 10.1111/andr.12092. Epub 2015 Sep 4.
6
Metabolomics Approach to Male Lower Urinary Tract Symptoms: Identification of Possible Biomarkers and Potential Targets for New Treatments.代谢组学方法在男性下尿路症状中的应用:寻找可能的生物标志物和新治疗方法的潜在靶点。
J Urol. 2018 May;199(5):1312-1318. doi: 10.1016/j.juro.2017.11.070. Epub 2017 Nov 22.
7
Correlation of tools for objective evaluation of infravesical obstruction of men with lower urinary tract symptoms.男性下尿路症状与膀胱下梗阻的客观评估工具的相关性。
Int Braz J Urol. 2019 Jul-Aug;45(4):775-781. doi: 10.1590/S1677-5538.IBJU.2018.0706.
8
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.度他雄胺联合坦索罗辛或单药治疗良性前列腺增生伴下尿路症状患者后国际前列腺症状评分变化的基线变量影响:CombAT 研究 4 年结果。
BJU Int. 2014 Apr;113(4):623-35. doi: 10.1111/bju.12500. Epub 2014 Jan 9.
9
Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population.代谢综合征相关因素对亚洲人群良性前列腺增生和下尿路症状发生发展的影响。
Medicine (Baltimore). 2019 Oct;98(42):e17635. doi: 10.1097/MD.0000000000017635.
10
Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.有症状的良性前列腺增生男性下尿路症状的严重程度反映了膀胱储尿功能障碍和膀胱出口梗阻的不同构成。
Int J Clin Pract. 2014 Jun;68(6):743-8. doi: 10.1111/ijcp.12364. Epub 2014 Jan 29.

本文引用的文献

1
The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.2000 年至 2019 年全球 204 个国家和地区良性前列腺增生的全球、区域和国家负担:2019 年全球疾病负担研究的系统分析。
Lancet Healthy Longev. 2022 Nov;3(11):e754-e776. doi: 10.1016/S2666-7568(22)00213-6. Epub 2022 Oct 20.
2
Role of Lactate in Inflammatory Processes: Friend or Foe.乳酸在炎症过程中的作用:是敌是友。
Front Immunol. 2022 Jan 14;12:808799. doi: 10.3389/fimmu.2021.808799. eCollection 2021.
3
IPSS "bother question" score predicts health-related quality of life better than total IPSS score.IPSS“困扰问题”评分比总 IPSS 评分更能预测健康相关生活质量。
World J Urol. 2022 Mar;40(3):765-772. doi: 10.1007/s00345-021-03911-2. Epub 2022 Jan 9.
4
Physiological Functions of Threonine in Animals: Beyond Nutrition Metabolism.苏氨酸在动物生理功能上的作用:超越营养代谢。
Nutrients. 2021 Jul 28;13(8):2592. doi: 10.3390/nu13082592.
5
Threonine, but Not Lysine and Methionine, Reduces Fat Accumulation by Regulating Lipid Metabolism in Obese Mice.苏氨酸而非赖氨酸和蛋氨酸通过调节肥胖小鼠的脂质代谢减少脂肪积累。
J Agric Food Chem. 2020 Apr 29;68(17):4876-4883. doi: 10.1021/acs.jafc.0c01023. Epub 2020 Apr 15.
6
The Appetite-Suppressant and GLP-1-Stimulating Effects of Whey Proteins in Obese Subjects are Associated with Increased Circulating Levels of Specific Amino Acids.乳清蛋白在肥胖受试者中的抑制食欲和 GLP-1 刺激作用与循环中特定氨基酸水平的升高有关。
Nutrients. 2020 Mar 15;12(3):775. doi: 10.3390/nu12030775.
7
Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and Plasma by H NMR Spectroscopy in a Multilaboratory Trial.采用 H NMR 光谱法在多实验室试验中对人血清和血浆中的定量脂蛋白亚类和低分子量代谢产物进行分析。
Anal Chem. 2018 Oct 16;90(20):11962-11971. doi: 10.1021/acs.analchem.8b02412. Epub 2018 Sep 27.
8
PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.PSA 预测下尿路症状的发生:来自 REDUCE 研究的结果。
Prostate Cancer Prostatic Dis. 2018 Jun;21(2):238-244. doi: 10.1038/s41391-018-0044-y. Epub 2018 May 23.
9
The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.微小 RNA 作为良性前列腺增生生物标志物的潜在作用:系统评价和荟萃分析。
Eur Urol Focus. 2019 May;5(3):497-507. doi: 10.1016/j.euf.2018.01.008. Epub 2018 Feb 3.
10
Metabolomics Approach to Male Lower Urinary Tract Symptoms: Identification of Possible Biomarkers and Potential Targets for New Treatments.代谢组学方法在男性下尿路症状中的应用:寻找可能的生物标志物和新治疗方法的潜在靶点。
J Urol. 2018 May;199(5):1312-1318. doi: 10.1016/j.juro.2017.11.070. Epub 2017 Nov 22.

利用代谢组学和偏最小二乘回归鉴定下尿路症状的潜在生物标志物。

Identifying possible biomarkers of lower urinary tract symptoms using metabolomics and partial least square regression.

机构信息

Department of Urology, Førde Central Hospital, Førde, Norway.

Department of Clinical Medicine, University of Bergen, Bergen, Norway.

出版信息

Metabolomics. 2023 Sep 12;19(9):82. doi: 10.1007/s11306-023-02046-2.

DOI:10.1007/s11306-023-02046-2
PMID:37698748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10497431/
Abstract

INTRODUCTION

The objective of this study was to explore potential novel biomarkers for moderate to severe lower urinary tract symptoms (LUTS) using a metabolomics-based approach, and statistical methods with significant different features than previous reported.

MATERIALS AND METHODS

The patients and the controls were selected to participate in the study according to inclusion/exclusion criteria (n = 82). We recorded the following variables: International prostatic symptom score (IPSS), prostate volume, comorbidities, PSA, height, weight, triglycerides, glycemia, HDL cholesterol, and blood pressure. The study of 41 plasma metabolites was done using the nuclear magnetic resonance spectroscopy technique. First, the correlations between the metabolites and the IPSS were done using Pearson. Second, significant biomarkers of LUTS from metabolites were further analysed using a multiple linear regression model. Finally, we validated the findings using partial least square regression (PLS).

RESULTS

Small to moderate correlations were found between IPSS and methionine (-0.301), threonine (-0.320), lactic acid (0.294), pyruvic acid (0.207) and 2-aminobutyric-acid (0.229). The multiple linear regression model revealed that only threonine (p = 0.022) was significantly associated with IPSS, whereas methionine (p = 0.103), lactic acid (p = 0.093), pyruvic acid (p = 0.847) and 2-aminobutyric-acid (p = 0.244) lost their significance. However, all metabolites lost their significance in the PLS model.

CONCLUSION

When using the robust PLS-regression method, none of the metabolites in our analysis had a significant association with lower urinary tract symptoms. This highlights the importance of using appropriate statistical methods when exploring new biomarkers in urology.

摘要

简介

本研究旨在通过代谢组学方法,探索中度至重度下尿路症状(LUTS)的潜在新型生物标志物,并使用与既往报道显著不同的统计方法。

材料与方法

根据纳入/排除标准(n=82),选择患者和对照参与研究。我们记录了以下变量:国际前列腺症状评分(IPSS)、前列腺体积、合并症、PSA、身高、体重、甘油三酯、血糖、高密度脂蛋白胆固醇和血压。使用核磁共振光谱技术对 41 种血浆代谢物进行研究。首先,使用 Pearson 分析代谢物与 IPSS 之间的相关性。其次,使用多元线性回归模型进一步分析与 LUTS 相关的显著生物标志物。最后,我们使用偏最小二乘回归(PLS)验证发现。

结果

发现 IPSS 与蛋氨酸(-0.301)、苏氨酸(-0.320)、乳酸(0.294)、丙酮酸(0.207)和 2-氨基丁酸(0.229)之间存在小到中度相关性。多元线性回归模型显示,只有苏氨酸(p=0.022)与 IPSS 显著相关,而蛋氨酸(p=0.103)、乳酸(p=0.093)、丙酮酸(p=0.847)和 2-氨基丁酸(p=0.244)失去了其显著性。然而,在 PLS 模型中,所有代谢物都失去了显著性。

结论

当使用稳健的 PLS 回归方法时,我们分析中的代谢物均与下尿路症状无显著关联。这强调了在泌尿科探索新生物标志物时使用适当的统计方法的重要性。